Evidence map›Paper›PMID 42455592›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Tumor-Associated Macrophage Exosomal miR-142-5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG/Ras/ERK Axis.

Bo-Han Lin, Jun-Ming Zhu, Zhen Kang, Jiang-Bo Sun, Zhong-Hua Zhu, Rui-Cheng Gao, Bin Lin, Ning Xu, Zhi-Bin Ke, Qing-Shui Zheng and 2 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bo-Han LinDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jun-Ming ZhuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zhen KangDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jiang-Bo SunDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zhong-Hua ZhuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Rui-Cheng GaoDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Bin LinDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Ning XuDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zhi-Bin KeDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Qing-Shui ZhengDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xue-Yi XueDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yong WeiDepartment of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0001-5324-3733

Funding

Fujian Provincial Finance Department BPB-2025WY-2Science and Technology Innovation Joint fund of Fujian Province 2023Y9078University-Industry Research Cooperation Project of Science and Technology, Fujian Province 2025Y4013
6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) for prostate cancer (PCa) leads to lineage plasticity in PCa cells, promoting the emergence of androgen receptor-negative neuroendocrine prostate cancer (NEPC). NEPC is a highly aggressive subtype with poor prognosis and limited treatment options. Tumor-associated macrophages (TAMs) contribute to tumor progression through exosome-mediated communication. In our previous study, we analyzed RNA-seq data to identify key genes involved in PCa progression, and the RERG gene emerged as a significant candidate that suppresses neuroendocrine differentiation (NED). In this study, we demonstrate that RERG expression is significantly reduced in CRPC cells and NEPC tissues, and its downregulation activates the Ras/ERK signaling pathway, which plays a crucial role in promoting NED. Additionally, miR-142-5p, transferred from TAMs via exosomes, downregulates RERG expression and activates the Ras/ERK pathway, thereby promoting PCa progression and NED. In vitro, miR-142-5p enhanced PCa cell proliferation, migration, invasion, and NED, while RERG overexpression reversed these effects. In vivo, RERG knockdown significantly promoted tumor growth and NED in a xenograft model. These findings highlight the role of TAM-derived miR-142-5p in regulating NED and suggest that targeting the RERG/Ras/ERK axis may provide a novel therapeutic approach for NEPC.

Indexed as

ExosomesMAP Kinase Signaling SystemMicroRNAsProstatic Neoplasmsras Guanine Nucleotide Exchange Factorsras ProteinsTumor-Associated MacrophagesAnimalsCell DifferentiationCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceMicroRNAsMIR142, humanras Guanine Nucleotide Exchange Factorsras Proteinsneuroendocrine differentiationprostate cancerRas/ERK pathwayRERGtumor‐associated macrophages

Identifiers

PMID42455592
PMCPMC13371989

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.